Is on! Brand Growth Enough to Offset MST Declines at Altria?

Altria's Q2 2025 results show its on! nicotine pouch brand shipments surged 26.5% year-over-year, driving a 10.9% increase in the oral tobacco segment's adjusted operating income as the category now comprises over half of the U.S. oral tobacco market. However, this growth was partially offset by significant retail share and volume declines for traditional moist smokeless tobacco brands like Copenhagen and Skoal. While on! is a critical growth engine, its share within the increasingly competitive nicotine pouch segment itself declined, underscoring intense pressure from rivals such as Philip Morris's rapidly expanding ZYN and Turning Point Brands' substantial Modern Oral sales growth. Altria's ability to sustain overall segment performance hinges on its capacity to secure further share gains in the evolving pouch market to effectively counter the ongoing erosion of its legacy products, despite recent stock outperformance and a favorable valuation relative to the industry.

Analysis

Altria Group's second quarter 2025 performance highlights a critical strategic pivot, with mixed results. The oral tobacco segment's adjusted operating income grew 10.9%, driven by a 26.5% year-over-year surge in shipments for its on! nicotine pouch brand. This growth is occurring as nicotine pouches now constitute over half of the U.S. oral tobacco market. However, this positive momentum is significantly challenged by the rapid decline of Altria's legacy moist smokeless tobacco (MST) products. The flagship Copenhagen and Skoal brands saw sharp volume declines of 7.7% and 8.8% respectively, contributing to a 4.6 percentage point drop in the segment's total retail share to 33.1%. Compounding this issue is the intensifying competition within the high-growth pouch category itself; on!'s share of the pouch segment contracted by 2.3 percentage points to 16.7%. This contrasts sharply with the aggressive expansion of rivals, including Philip Morris's ZYN, which saw 26% U.S. offtake growth, and Turning Point Brands, whose Modern Oral sales increased nearly eightfold. While Altria's stock has gained 10.5% in the past month and trades at a favorable forward P/E of 11.7X compared to the industry average of 15.36X, the fundamental question remains whether on!'s growth can successfully outpace both the erosion of its legacy business and the formidable market share gains of its competitors.

Key Decisions for Investors

• Investors should weigh Altria's attractive valuation and the strong absolute growth of its on! brand against the significant risk posed by accelerating declines in its legacy moist smokeless tobacco business.
• Monitor on!'s market share within the nicotine pouch segment very closely, as its recent 2.3 percentage point decline to 16.7% amidst fierce competition from Philip Morris's ZYN and Turning Point Brands is a key indicator of future profitability.
• Consider the sustainability of the recent 10.5% stock price appreciation, as the underlying fundamentals show a company struggling to defend market share in both its declining legacy and its core growth categories.